The Necrotizing Enterocolitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Necrotizing Enterocolitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Necrotizing Enterocolitis Market.
Some of the key takeaways from the Necrotizing Enterocolitis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Necrotizing Enterocolitis treatment therapies with a considerable amount of success over the years.
- Necrotizing Enterocolitis companies working in the treatment market are NEC Evolve Biosystems, Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Infant Bacterial Therapeutics, The Emmes Company, LLC, and others, are developing therapies for the Necrotizing Enterocolitis treatment
- Emerging Necrotizing Enterocolitis therapies in the different phases of clinical trials are- Research Programme, STMC-106, ST266, MRG1061, IBP-9414, meropenem, and others are expected to have a significant impact on the Necrotizing Enterocolitis market in the coming years.
- In January 2023, The British Journal of Gastroenterology provides clinical findings from Infant Bacterial Therapeutics (IBT) regarding the compelling correlation between clinical events and the feeding primary goal of the “ConnectionStudy.” Two separate primary objectives are being tracked in the “Connection Study” about the pharmaceutical grade probiotic IBP-9414: the incidence of necrotizing enterocolitis (NEC) and the time to a rigorous definition of sustained feeding tolerance (SFT).
- In January 2022, The Australian Patent Office has issued a patent entitled “A method of activating lactic acid bacteria,” which protects the formulation of Lactobacillus reuteri, including IBP-9414, according to a statement released by Infant Bacterial Therapeutics AB. Phase III research on IBP9414 is aimed at preventing necrotizing enterocolitis (NEC) and enhancing feeding tolerance in premature newborns.
Necrotizing Enterocolitis Overview
The debilitating condition known as necrotizing enterocolitis (NEC) primarily attacks the intestines of premature newborns. Bacteria infiltrate the intestinal wall, resulting in localized infection and inflammation that may eventually lead to the wall’s destruction (intestine). Such damage to the bowel wall may result in intestinal perforation and the leakage of stool into the baby’s abdomen, potentially leading to a fatal infection.
Get a Free Sample PDF Report to know more about Necrotizing Enterocolitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/necrotizing-enterocolitis-pipeline-insight
Emerging Necrotizing Enterocolitis Drugs Under Different Phases of Clinical Development Include:
- Research Programme: NEC Evolve Biosystems
- STMC-106: Siolta Therapeutics
- ST266: Noveome Biotherapeutics
- MRG1061: Micregen Ltd
- IBP-9414: Infant Bacterial Therapeutics
- meropenem: The Emmes Company, LLC
Necrotizing Enterocolitis Route of Administration
Necrotizing Enterocolitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical.
- Molecule Type
Necrotizing Enterocolitis Molecule Type
Necrotizing Enterocolitis Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Necrotizing Enterocolitis Pipeline Therapeutics Assessment
- Necrotizing Enterocolitis Assessment by Product Type
- Necrotizing Enterocolitis By Stage and Product Type
- Necrotizing Enterocolitis Assessment by Route of Administration
- Necrotizing Enterocolitis By Stage and Route of Administration
- Necrotizing Enterocolitis Assessment by Molecule Type
- Necrotizing Enterocolitis by Stage and Molecule Type
DelveInsight’s Necrotizing Enterocolitis Report covers around 4+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Necrotizing Enterocolitis product details are provided in the report. Download the Necrotizing Enterocolitis pipeline report to learn more about the emerging Necrotizing Enterocolitis therapies
Some of the key companies in the Necrotizing Enterocolitis Therapeutics Market include:
Key companies developing therapies for Necrotizing Enterocolitis are – Abbott, Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson, and Company (BD), Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Eli Lilly and Co., Enzon Pharmaceuticals, Inc., Hoffmann-La Roche Ltd, GI Supply, GlaxoSmithKline Plc, and others.
Necrotizing Enterocolitis Pipeline Analysis:
The Necrotizing Enterocolitis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Necrotizing Enterocolitis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Necrotizing Enterocolitis Treatment.
- Necrotizing Enterocolitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Necrotizing Enterocolitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Necrotizing Enterocolitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Necrotizing Enterocolitis drugs and therapies
Necrotizing Enterocolitis Pipeline Market Drivers
- Increasing contribution towards the research and development activities, improved regulatory framework by the Government towards the development of new antibiotics and therapies are some of the important factors that are fueling the Necrotizing Enterocolitis Market.
Necrotizing Enterocolitis Pipeline Market Barriers
- However, high cost associated with the treatment, lack of skilled healthcare professionals to carry out the diagnosis and other factors are creating obstacles in the Necrotizing Enterocolitis Market growth.
Scope of Necrotizing Enterocolitis Pipeline Drug Insight
- Coverage: Global
- Key Necrotizing Enterocolitis Companies: NEC Evolve Biosystems, Siolta Therapeutics, Noveome Biotherapeutics, Micregen Ltd, Infant Bacterial Therapeutics, The Emmes Company, LLC, and others
- Key Necrotizing Enterocolitis Therapies: Research Programme, STMC-106, ST266, MRG1061, IBP-9414, meropenem, and others
- Necrotizing Enterocolitis Therapeutic Assessment: Necrotizing Enterocolitis current marketed and Necrotizing Enterocolitis emerging therapies
- Necrotizing Enterocolitis Market Dynamics: Necrotizing Enterocolitis market drivers and Necrotizing Enterocolitis market barriers
Request for Sample PDF Report for Necrotizing Enterocolitis Pipeline Assessment and clinical trials
Table of Contents
1. Necrotizing Enterocolitis Report Introduction
2. Necrotizing Enterocolitis Executive Summary
3. Necrotizing Enterocolitis Overview
4. Necrotizing Enterocolitis- Analytical Perspective In-depth Commercial Assessment
5. Necrotizing Enterocolitis Pipeline Therapeutics
6. Necrotizing Enterocolitis Late Stage Products (Phase II/III)
7. Necrotizing Enterocolitis Mid Stage Products (Phase II)
8. Necrotizing Enterocolitis Early Stage Products (Phase I)
9. Necrotizing Enterocolitis Preclinical Stage Products
10. Necrotizing Enterocolitis Therapeutics Assessment
11. Necrotizing Enterocolitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Necrotizing Enterocolitis Key Companies
14. Necrotizing Enterocolitis Key Products
15. Necrotizing Enterocolitis Unmet Needs
16 . Necrotizing Enterocolitis Market Drivers and Barriers
17. Necrotizing Enterocolitis Future Perspectives and Conclusion
18. Necrotizing Enterocolitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services